Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

The Associated Press November 14, 2011, 6:39PM ET

Geron halting stem cell research, laying off staff

Money troubles have forced the first company doing a government-approved test of embryonic stem cell therapy to discontinue further stem cell programs and lay off much of its staff.

Geron Corp. said late Monday that it is halting development of its stem cell programs and seeking partners to take on their assets.

Geron, based in Menlo Park, Calif., will focus instead on cancer research, particularly its drugs that are in mid-stage human testing.

The company said it is eliminating 66 full-time jobs, or 38 percent of its staff, a process that will bring about $8 million in costs between now and next June.

Geron in October 2010 began testing an embryonic stem cell therapy in patients with recent spinal cord injuries.

BW Mall - Sponsored Links

Buy a link now!